Udager Aaron M, Chiosea Simion I
Department of Pathology, University of Michigan Health System, 1500 E. Medical Center Dr., Ann Arbor, MI, 48109, USA.
Department of Pathology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA, 15213, USA.
Head Neck Pathol. 2017 Sep;11(3):288-294. doi: 10.1007/s12105-017-0798-x. Epub 2017 Mar 20.
More than 15 years ago, seminal studies by Dr. E. Leon Barnes and colleagues transformed our understanding of salivary duct carcinoma (SDC) and, in doing so, paved the way for contemporary diagnostic and therapeutic approaches to this aggressive salivary adenocarcinoma. In particular, attention to the apocrine phenotype of SDC and expression of androgen receptor (AR) by immunohistochemistry has improved the diagnostic accuracy and showed how SDC can be reliably distinguished from its morphologic mimics (i.e., other salivary gland carcinomas with high grade transformation, low grade cribriform cystadenocarcinoma, and squamous cell carcinomas involving parotid). Furthermore, the observation that SDC shares AR expression with prostate cancer and apocrine breast cancer foresaw the discovery of common molecular alterations between SDC and these tumor types and draw attention to androgen deprivation therapy for SDC patients.
15年多前,E. 利昂·巴恩斯博士及其同事的开创性研究改变了我们对涎腺导管癌(SDC)的认识,从而为这种侵袭性涎腺腺癌的当代诊断和治疗方法铺平了道路。特别是,对SDC顶泌汗腺样表型的关注以及通过免疫组织化学检测雄激素受体(AR)的表达提高了诊断准确性,并展示了如何可靠地将SDC与其形态学上的模仿者(即其他伴有高级别转化的涎腺癌、低级别筛状囊腺癌和累及腮腺的鳞状细胞癌)区分开来。此外,SDC与前列腺癌和顶泌汗腺样乳腺癌共享AR表达这一观察结果预示了SDC与这些肿瘤类型之间共同分子改变的发现,并引起了对SDC患者雄激素剥夺治疗的关注。